Education
About Us
Working with TipRanks
Follow Us
Jasper Therapeutics (JSPR)
NASDAQ:JSPR
JSPR Stock Chart & Stats
$1.23
-$10.02(-56.58%)
At close: 4:00 PM EST
$1.23
-$10.02(-56.58%)
Day’s Range― - ―
52-Week Range$1.11 - $7.19
Previous CloseN/A
Volume4.28M
Average Volume (3M)399.98K
Market Cap
$34.42M
Enterprise Value-$29.21M
Total Cash (Recent Filing)$50.90M
Total Debt (Recent Filing)$1.70M
Price to Earnings (P/E)―
Beta2.51
Next Earnings
May 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding27,984,040
10 Day Avg. Volume455,991
30 Day Avg. Volume399,984
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)5.06
Price to Sales (P/S)0.00
P/FCF Ratio-4.94
Enterprise Value/Market Cap-0.85
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.32
Forecast
1Y Price Target
$10.63Price Target Upside763.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)-2.41
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyUpdated trial data show rapid symptom relief and high rates of complete responses, which could support strong market interest if confirmed in ongoing development.
Durability Of ResponseOpen-label extension results indicate a substantial proportion of patients maintained benefit on the maintenance regimen, suggesting durable disease control that may enhance long-term value.
Leadership And ExecutionAppointment of a new CEO with decades of life sciences leadership is viewed as supportive for strategic execution and may improve investor confidence around program advancement.
Bears Say
Dosing UncertaintyTemporary drops in response linked to patient weight and small cohort variability highlight dosing uncertainty that may require alternative schedules or weight-based adjustments to ensure consistent efficacy.
Financing PressureNeed to raise additional capital for the mid-stage trial creates financing pressure that could lead to dilution or slow progress if funding is not secured on favorable terms.
Trial Quality And IntegrityAnalyst concerns about potential drug lot issues and incorrect patient enrollment raise questions about trial quality that could undermine regulatory review and investor trust.
Jasper Therapeutics News
JSPR FAQ
What was Jasper Therapeutics’s price range in the past 12 months?
Jasper Therapeutics lowest stock price was $1.11 and its highest was $7.19 in the past 12 months.
What is Jasper Therapeutics’s market cap?
Jasper Therapeutics’s market cap is $34.42M.
When is Jasper Therapeutics’s upcoming earnings report date?
Jasper Therapeutics’s upcoming earnings report date is May 08, 2026 which is in 45 days.
How were Jasper Therapeutics’s earnings last quarter?
Currently, no data Available
Is Jasper Therapeutics overvalued?
According to Wall Street analysts Jasper Therapeutics’s price is currently Undervalued.
Does Jasper Therapeutics pay dividends?
Jasper Therapeutics does not currently pay dividends.
What is Jasper Therapeutics’s EPS estimate?
Jasper Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Jasper Therapeutics have?
Jasper Therapeutics has 27,984,040 shares outstanding.
What happened to Jasper Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Jasper Therapeutics?
Currently, no hedge funds are holding shares in JSPR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Jasper Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.63 (763.82% Upside)
$10.63 (763.82% Upside)
Hedge Fund Trend
Increased
By 953.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days >0.1%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-92.39%
12-Months-Change
Fundamentals
Return on Equity
-191.12%
Trailing 12-Months
Asset Growth
-42.19%
Trailing 12-Months
Company Description
Jasper Therapeutics
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The company's lead product candidate is JSP191, which is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.
JSPR Stock 12 Month Forecast
Average Price Target
$10.63
▲(763.82% Upside)
Technical Analysis
Ownership Overview
1.34% Insiders
6.49% Mutual Funds
35.16% Other Institutional Investors
52.66% Public Companies and
Individual Investors